U.S. Drug Delivery Systems Market

Content

• 1. Introduction to Drug Delivery Systems
  • 1.1 Overview of Drug Delivery Systems
    • 1.1.1 What Drug Delivery Systems Are
    • 1.1.2 What Drug Delivery Systems Can Do
  • 1.2 Big Picture of Pharma Development Trends Important to Drug Delivery
    • 1.2.1 The Pharmaceutical Industry is Facing a Productivity Gap
    • 1.2.2 Profitable Drugs To Lose Patent Protection and Market Exclusivity
    • 1.2.3 Major Pharma Companies are Using Patent Extension Strategies
  • 1.3 Drug Development Often Requires Using Outsourced Partners
    • 1.3.1 Many New Drugs are Expected to Hit the Market in 3-4 Years
    • 1.3.2 Big Pharmas Cannot Work Alone to Make Drugs
  • 1.4 Goal of Developing Drug Delivery Technologies
  • 1.5 Rationale for Developing Drug Delivery Systems
    • 1.5.1 Commercial Interests
    • 1.5.2 Post-Genomic Advances and Emerging Targeted Therapies
    • 1.5.3 Large Molecule Biopharmaceurticals: Protein and Peptide Drugs
    • 1.5.4 More Knowledge About Disease Mechanisms
  • 1.6 Challenges for Drug Delivery Companies
    • 1.6.1 Market is Fragmented
    • 1.6.2 The Field Has Grown Quickly
  • 1.7 Future Outlook
    • 1.7.1 More Growth Expected in Next Few Years
    • 1.7.2 Drug Delivery Technologies Preferred by the Pharma Industry
    • 1.7.3 Drug Delivery Business Models are Shifting to Self-Marketing.
• 2. Technologies Developed for Drug Delivery Systems
  • 2.1 Oral Drug Delivery
  • 2.2 Injection Based Drug Delivery
  • 2.3 Transdermal Drug Delivery
  • 2.4 Transmucosal Drug Delivery
  • 2.5 Bone Marrow Infusion
  • 2.6 Organ System Specific Drug Delivery
    • 2.6.1 Pulmonary Drug Delivery
    • 2.6.2 Nasal Delivery to Central Nervous System (CNS)
    • 2.6.3 Cardiovascular System (CV)
    • 2.6.4 Gastro-Intestinal Tract (GI)
    • 2.6.5 Genito-Urinary Tract (GU)
    • 2.6.6 Ocular Drug Delivery
  • 2.7 Controlled Release Systems
  • 2.8 Novel Packaging and Formulations
    • 2.8.1 Fast Dissolving Tablets
    • 2.8.2 Chewable Tablets
    • 2.8.3 Solubility Enhancement
  • 2.9 Highly Targeted Drug Delivery
    • 2.9.1 Polymer and Collagen Systems
    • 2.9.2 Particle-Based Systems
      • 2.9.2.1 Therapeutic Monoclonal Antibodies.
      • 2.9.2.2 Liposomes
      • 2.9.2.3 Microparticles
      • 2.9.2.4 Modified Blood Cells
      • 2.9.2.5 Nanoparticles
      • 2.9.2.6 Viral Assisted Intracellular Gene Delivery
      • 2.9.2.7Non-Viral Intracellular Gene Delivery
• 3.Strategic Alliances and M&As by Companies Involved in Drug Delivery Systems
• 4. Selected Drug Delivery Patent Disputes
  • 4.1 Andrx Corporation Patent Disputes
    • 4.1.1 AstraZenica v. Andrx and Others
    • 4.1.2 Biovail v. Andrx
  • 4.2 Watson Pharmaceuticals v. Bristol Myers-Squibb
  • 4.3 Valentis, Inc. v. Alza Corporation
  • 4.4 Bectin Dickenson v. Tyco Healthcare
  • 4.4Guidant Corp. v. Boston Scientific
• 5.Applied and Emerging Technology Status for Drug Delivery
• 6. The Market for Drug Delivery Systems and Future Outlook
  • 6.1 US Drug Delivery Market Trends
    • 6.1.1 A Significant Market
    • 6.1.2 Solutions for Unmet Medical Needs
    • 6.1.3 Doctors and Patients Prefer No Pain
    • 6.1.4 Drug Delivery Helps Pharmaceutical Firms to Compete
  • 6.2 US Drug Delivery Market Size by Segment 2001-2006
    • 6.2.1 Market Segments
    • 6.2.2 Oral Drug Delivery
    • 6.2.3 Injectable Drug Delivery
    • 6.2.4 Injection Devices
    • 6.2.5 Inhaled Drug Delivery
    • 6.2.6 Inhaler Devices (MDI, DPI, Nebulizer, Liquid)
    • 6.2.7 Transdermal Drug Delivery
    • 6.2.8 Implant Drug Delivery
    • 6.2.9 Transmucosal Drug Delivery
    • 6.2.10 Therapeutic Antibodies
    • 6.2.11 Therapeutic & Cancer Vaccines
    • 6.2.12 Gene Therapy/Delivery
    • 6.2.13 Other Drug Delivery
    • 6.2.14 Market Shares of the US Drug Delivery Market, 2001 and 2006
  • 6.1Map of New Ventures and Products/Platforms
• 7. Emerging Nanotechnology and Drug Delivery R&D
  • 7.1 Current Status of Nanotechnology Drug Delivery Market
  • 7.2 Technology to be Developed
  • 7.3 Commercial Implications
  • 7.4 Venture Nanotech R&D Companies' Activities
• 8.The World Top 50 Drug Delivery Companies
• 9. Activities of Leading Drug Delivery Firms for R&D
  • 9.1 Big Pharma (2)
  • 9.2 Cancer Therapy (2)
  • 9.3 End-to-End Delivery Platforms (3)
  • 9.4 Targeted Delivery, Monoclonal Antibodies (2)
  • 9.5 Nanotechnology Drug Delivery (3)
  • 9.6 Inhaled Delivery (2)
  • 9.7 Speciality Pharma (3)
  • 9.8 Transdermal/Transmucosal (2)
  • 9.9 Vaccine Delivery (2)
• 10. Appendix A: Links to Drug Delivery Websites
  • 10.1 Pharmaceutical Industry Sites
  • 10.2 Government Regulatory Agencies
  • 10.3 Pharmaceutical Industry News Sites
• 11. Appendix B: Glossary of Drug Delivery Terms
• List Of Tables
  • Table 1. US Drug Delivery Systems (DDS) Market Size, 2001-2006
  • Table 2. Analysis of Alliances and M&As of DDS Companies
  • Table 3. Drug Delivery Company Alliances in 2002
  • Table 4. Drug Delivery Company Alliances in 2001
  • Table 5. Drug Delivery Company Alliances in 2000
  • Table 6. Drug Delivery Company Alliances from Mar.- Dec. 1999
  • Table 7. Summary of Selected Drug Delivery Patent Disputes
  • Table 8. Applied and Emerging Technology Summary
  • Table 9. Emerging Drug Delivery Technology Status in 2002
  • Table 10. US Drug Delivery Market Size, Revenues by Segments 2001-2006
  • Table 11. US DDS Market Revenues by Share, 2001 and 2006
  • Table 12. Map of New Ventures and Products
  • Table 13. C Sixty Inc.
  • Table 14. NTera Ltd.
  • Table 15. MicroCHIPS Inc.
  • Table 16. Molecular Express Inc.
  • Table 17. Capsulution NanoScience AG
  • Table 18. Aphios Corporation
  • Table 19. Nanotherapeutics Inc.
  • Table 20. iMEDD Inc.
  • Table 21. Advectus Life Sciences Inc.
  • Table 22. The World 50 Drug Delivery Companies by Revenues (2001 $M)
• List of Figures
  • Figure 1. US Drug Delivery Systems (DDS) Market Size, 2001-2006
  • Figure 2. The GI Tract and Oral Drug Delivery Route (by Mouth)
  • Figure 3. Injection Based Drug Delivery Methods
  • Figure 4. Transdermal Patch Drug Delivery
  • Figure 5. Noven Pharmaceuticals' DOT Matrix Patch
  • Figure 6. Intraosseous (Bone Marrow) Infusion
  • Figure 7. Nektar's Inhance(tm) Pulmonary Delivery Solution
  • Figure 8. Pulmonary Delivery
  • Figure 9. Johnson & Johnson's Drug-Coated Stent
  • Figure 10. SkyePharma's Controlled Release Drug
  • Figure 11. US Drug Delivery Market Size, Revenues by Segments 2001-2006
  • Figure 12. US DDS Market Revenues by Share, 2001 and 2006